Paradis I
Oklahoma Transplantation Institute, INTEGRIS Baptist Medical Center, Oklahoma City 73112, USA.
Am J Med Sci. 1998 Mar;315(3):161-78. doi: 10.1097/00000441-199803000-00005.
Increasing early success-post lung transplant has been tempered by the long-term development of histologic bronchiolitis obliterans (OB) or of the progressive airway obstruction which is called bronchiolitis obliterans syndrome (BOS). Multiple lines of evidence suggest that OB/BOS is due to an injury directed against the epithelial cells in the airways of the donor lung by the immune system of the recipient. Acute rejection is the strongest risk factor for the subsequent development of this process. Efforts to prevent or minimize acute rejection may reduce the prevalence of OB/BOS. Results of treatment with augmented immunosuppression have been disappointing but the treatment of complicating infections in the allograft can be beneficial. Multicenter studies are needed to assess the efficacy of new immunosuppressive agents in preventing or treating OB/BOS.
肺移植术后早期成功率的提高受到组织学上闭塞性细支气管炎（OB）或称为闭塞性细支气管炎综合征（BOS）的进行性气道阻塞长期发展的影响。多条证据表明，OB/BOS是由于受者免疫系统针对供体肺气道上皮细胞的损伤所致。急性排斥反应是该过程后续发展的最强危险因素。预防或尽量减少急性排斥反应的努力可能会降低OB/BOS的发生率。强化免疫抑制治疗的结果令人失望，但治疗同种异体移植物中的并发感染可能有益。需要进行多中心研究来评估新型免疫抑制剂在预防或治疗OB/BOS方面的疗效。
